These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26839197)

  • 1. The Differential Diagnosis of Eosinophilia in Neoplastic Hematopathology.
    Johnson RC; George TI
    Surg Pathol Clin; 2013 Dec; 6(4):767-94. PubMed ID: 26839197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.
    Vega F; Medeiros LJ; Bueso-Ramos CE; Arboleda P; Miranda RN
    Am J Clin Pathol; 2015 Sep; 144(3):377-92. PubMed ID: 26276769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilic myeloid neoplasms.
    Noel P; Mesa RA
    Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
    Savage N; George TI; Gotlib J
    Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
    Gotlib J
    Curr Hematol Malig Rep; 2015 Dec; 10(4):351-61. PubMed ID: 26404639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical myeloproliferative disorders in adults.
    Zachée P
    Transfus Apher Sci; 2011 Apr; 44(2):211-21. PubMed ID: 21402312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.
    Szymczyk A; Jaworski J; Podhorecka M
    Cent Eur J Immunol; 2024; 49(1):60-69. PubMed ID: 38812609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.